<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="ranging from 10 to 20%. In 1998, the oral drug" exact="ribavirin" post="was added to interferon. The therapeutic response rates increased"/>
 <result pre="this drug. In 2011, two protease inhibitors were introduced namely" exact="boceprevir" post="and telaprevir.[47] Treatment of chronic HCV with PEG-IFN and"/>
 <result pre="boceprevir and telaprevir.[47] Treatment of chronic HCV with PEG-IFN and" exact="ribavirin" post="and, more recently, with PEG-IFN plus ribavirin and first-generation"/>
 <result pre="with PEG-IFN and ribavirin and, more recently, with PEG-IFN plus" exact="ribavirin" post="and first-generation protease inhibitors (Telaprevir and Boceprevir) for HCV-1,"/>
 <result pre="may interact with HIV antiretrovirals (nucleoside reverse transcriptase inhibitors) and" exact="ribavirin" post="Can cause mitochondrial toxicity Nucleos(t) ide analog NS5B polymerase"/>
 <result pre="management by impacting the duration of therapy and/or inclusion of" exact="ribavirin" post="or result in selection of alternative therapy. However, at"/>
 <result pre="for 12 weeks of sofosbuvir/velpatasvir. If Y93H is present, weight-based" exact="ribavirin" post="should be added or sofosbuvir/velpatasvir/voxilaprevir should be used. I,"/>
 <result pre="added or sofosbuvir/velpatasvir/voxilaprevir should be used. I, A Daclatasvir plus" exact="sofosbuvir" post=" NS5A RAS testing is recommended for genotype 3-infected, treatment-experienced"/>
 <result pre="treatment-experienced patients without cirrhosis being considered for 12 weeks of" exact="daclatasvir" post="plus sofosbuvir. If Y93H is present, weight-based ribavirin should"/>
 <result pre="weeks of daclatasvir plus sofosbuvir. If Y93H is present, weight-based" exact="ribavirin" post="should be added.  NS5A RAS testing is recommended for"/>
 <result pre="treatment-naive patients with cirrhosis being considered for 24 weeks of" exact="daclatasvir" post="plus sofosbuvir. If Y93H is present, treatment should include"/>
 <result pre="I, A Paritaprevir/ritonavir/ombitasvir with dasabuvir±weight-based ribavirin, or paritaprevir/ritonavir/ombitasvir + weight-based" exact="ribavirin" post=" RAS testing is not recommended for genotype 1- or"/>
 <result pre="-experienced patients being considered for therapy with paritaprevir/ritonavir/ombitasvir with dasabuvir±weight-based" exact="ribavirin" post="or paritaprevir/ritonavir/ombitasvir + weight-based ribavirin, respectively. I, A Sofosbuvir/velpatasvir"/>
 <result pre="resistance in genotype 1-6 hepatitis C virus-infected subjects treated with" exact="sofosbuvir" post="in phase 2 and 3 clinical trialsClin Infect Dis20145916667425266287"/>
</results>
